We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Rsv4.5
Resveratrol Research
Likely helps
198 peer-reviewed studies
What the evidence says
Likely helps
Resveratrol appears to help in 9 of 11 studies with measurable effects — the evidence leans clearly favourable.
Most evidence is from high-quality meta-analyses and randomised trials published 2011–2026 with a typical study size of 166 participants.
Based on 198 studies · 68 meta-analyses · 75 RCTs · 18,192 total participants
Confidence
High confidence
What the studies found
9helped2unclear· 187 more without graded effect data
By outcome
Heart & blood pressureModestly improves endothelial function in pooled trials · 4-8 weeks
Likely helps190 studies
Glucose & metabolicReduces insulin resistance in type 2 diabetes; no anti-obesity effect · 8-12 weeks
Likely helps33 studies
InflammationModestly lowers CRP and TNF-a in some trials · 4-8 weeks
2Non-alcoholic fatty liver disease parametersMeta-AnalysisCited 64×n=2,173 · very large study2022
Based on current evidence, curcumin can reduce BMI, TG, TC, liver enzymes, and insulin resistance; catechin can reduce BMI, insulin resistance, and TG effectively; silymarin can reduce liver enzymes.
Yang K et al. · Frontiers in immunology (2022)
Based on current evidence, curcumin can reduce BMI, TG, TC, liver enzymes, and insulin resistance; catechin can reduce BMI, insulin resistance, and TG effectively; silymarin can reduce liver enzymes.
For resveratrol, naringenin, anthocyanin, hesperidin, and catechin, more RCTs are needed to further evaluate their efficacy and safety.
3Multiple health outcomes across 24 indicationsSystematic ReviewCited 93×n=200 · medium study2024
In conclusion, over the last 20 years, the increasing weight of clinical evidence suggests resveratrol can benefit human health, but more large, high-quality clinical trials are required to transition this intriguing compound from health food shops to the clinic.
Brown K et al. · International journal of molecular sciences (2024)
Over the last 20 years, there have been almost 200 studies evaluating resveratrol across at least 24 indications, including cancer, menopause symptoms, diabetes, metabolic syndrome, and cardiovascular disease.
There are currently no consensus treatment regimens for any given condition or endpoint, beyond the fact that resveratrol is generally well-tolerated at a dose of up to 1 g/day.
Additionally, resveratrol consistently reduces inflammatory markers and improves aspects of a dysregulated metabolism.
4Skin wound healing improvementSystematic ReviewCited 93×n=826 · large study2022
The included studies showed promising results that resveratrol might be a feasible treatment approach to support wound healing, counteract excessive scarring, and even prevent photo-aging of the skin.
Hecker A et al. · International wound journal (2022)
The literature search yielded a total of 826 studies, but only 41 studies met the inclusion criteria.
The included studies showed promising results that resveratrol might be a feasible treatment approach to support wound healing, counteract excessive scarring, and even prevent photo-aging of the skin.
Resveratrol represents an interesting and promising novel therapy regime but to confirm resveratrol-associated effects, more evidence based in vitro and in vivo studies are needed.
5Inflammatory markers (TNF-α, hs-CRP)Meta-Analysisn=736 · large study2018
Available evidence from RCTs suggests that resveratrol supplementation significantly reduced TNF-α and hs-CRP levels.
Koushki M et al. · Clinical Therapeutics (2018)
The results of meta-analysis found significant reductions in the level of TNF-α (WMD, -0.44; 95% CI, -0.71 to -0.164; P = 0.002) and hs-CRP (WMD, -0.27; 95% CI, -0.5 to -0.02; P = 0.033) after supplementation with resveratrol.
Resveratrol supplementation had no significant effect on the level of IL-6 (WMD, -0.16; 95% CI, -0.53 to 0.20; P = 0.38).
Seventeen RCTs, including 736 subjects, fulfilled the eligibility criteria.